Expression and clinical significance of OPN and COX-2 in osteosarcoma

Abstract

Materials and methods MaterialsFifty-seven patients with osteosarcoma of bone and 11 osteoblastoma specimens were selected from the files of the Department of Clinical Pathology, Tongji Hospital. All cases were reviewed to confirm the diagnosis and a paraffin block of osteosarcoma biopsy material prior to Abstract Objective: To detect the expression of osteopontin (OPN) in benign and malignant bone tumors and investigate the prognostic influence of OPN expression on the outcome of osteosarcoma patients. Methods: Fifty-seven osteosarcomas and 11 osteoblastomas as well as 5 bone specimens with remodeling sites were immunohistochemically analyzed for expression of OPN and cyclooxygenase-2 (COX-2). Results: OPN was not detected in osteoblasts of remodeling sites. Osteoblastoma osteoblasts as well as osteoclastlike giant cells and osteosarcoma mononuclear cells showed variable staining. In osteosarcomas OPN and COX-2 expression correlated with each other (r = 0.390, P = 0.003, Spearman's test). Although osteosarcoma patients with high COX-2 expression showed a trend towards shorter overall survival (P = 0.0841, log-rank test), OPN expression had no influence on patients overall or on disease-free survival. Conclusion: Our data indicated that expression of this protein might be unregulated in bone neoplasia. Although OPN expression correlates with COX-2 expression in osteosarcomas, OPN expression does not provide predictive information about the outcome of osteosarcoma patients.

Analysis of angiogenic factors and cyclooxygenase-2 expression in cartilaginous tumors – clinical and histological correlation

“…In contrast, Dinckens et al27 found no correlation between COX-2 over-expression and patient outcome. Finally, Masi et al28 and Liao et al29 reported that cases of osteosarcoma had worse prognosis and decreased patient survival rates whether COX-2 was overexpressed. We suggest the following two reasons for these discordant results: 1) the COX-2 antibody clone that we used was different from that used by Endo et al; and/or 2) any problems with the fixation or decalcification of the samples could have biased the results.…”

“…Indeed, recent studies of various human tumors showed that COX-2 over-expression is associated with poor prognosis 21. In musculoskeletal tumors (e.g., osteosarcomas, rhabdomyosarcomas, and CSs), studies of COX-2 over-expression have yielded conflicting results 21-29…”

Role of osteopontin in osteosarcoma

“…Sulzbacher et al [28] determined the expression of OPN and found to be up-regulated in OS patients. In another study, Liao et al [29] detected the expression of OPN in fifty-seven OS patients and reported to be higher level in OS patients.…”

The cancer‐related transcription factor RUNX2 modulates expression and secretion of the matricellular protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis

“…As a whole, our study and those from others strongly suggest that RUNX2 may regulate osteosarcoma metastasis through a positive modulation of SPP1 gene expression, OPN secretion, and activation of osteopontin receptors involved in tumor cell adhesion to lung endothelium [Color figure can be viewed at wileyonlinelibrary.com] VILLANUEVA ET AL. | 13673 about the outcome of osteosarcoma patients, despite that RUNX2 mRNA levels from the same set of samples correlated with poor response to chemotherapy in two of these studies (Liao, Li, & Hu, 2007;Martin et al, 2014;Sadikovic et al, 2010;Sulzbacher, Birner, Trieb, Lang, & Chott, 2002,). Paradoxically, the analysis of osteopontin mRNA levels in another set of osteosarcoma tumor samples shows that overexpression of osteopontin correlated with good chemotherapy response, better overall survival, event-free survival, and relapse-free survival and diagnosis (Dalla-Torre et al, 2006;Endo-Munoz, Cumming, Sommerville, Dickinson, & Saunders, 2010).…”